© 2014 PrimeVax Immuno-Oncology

PrimeVax

Pipeline

As of mid 2019, PrimeVax is a fully clinically-enabled biotech with existing human safety data. Trial sites are currently being mobilized prior to patient enrollment. 

Technology Platform

PrimeVax’s therapy is a combination dendritic cell and virus therapy that is designed to identify and then eradicate tumor cells within the body. See below a summary of our technology:

 

Autologous DC

PV-001-DC

Description

Patient’s own dendritic cells combined with patient’s own cancer cells. 

Dengue Virus

PV-001-DV

Virus greatly boosts patient’s immune system.

Novelty

Already established as safe approach for increasing CTL by the FDA. 

Dengue virus kills tumors on contact and also have whole-body fever inducing capabilities

Our treatment is currently designed as an in-patient therapy on the basis of a hospital stay and patient monitoring procedures. To date, our therapeutic approach has been shown to work pre-clinically in melanoma, lung, and breast tumors. We intend to apply our technology to at least 17 different cancer types.